Alnylam Pharmaceuticals, Inc. (ALNY) Posts Narrower than Expected Q1 Loss

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q1 EPS of ($0.25), $0.11 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.57 million.

For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• Is the global equity rally broadening? UBS weighs in